BioVariance
BioVariance GmbH is a Bavarian precision medicine company that uses proprietary AI and bioinformatics platforms (OncoVariant, TubeLab, BioCore Studio) to deliver personalized diagnostics, genetic variant interpretation for oncologists, PCR and LC-MS/MS laboratory services, and a direct-to-consumer telomere self-test, serving healthcare providers, pharmaceutical partners, and clinical research consortia.
- Company typePrivate
- Founded2013
- HeadquartersTirschenreuth, Germany
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What BioVariance does
BioVariance GmbH is a privately held data-driven diagnostics and precision medicine company headquartered in Tirschenreuth, Bavaria, Germany, founded in 2013 by Dr. Josef Scheiber. The company operates an interdisciplinary model combining biologists, chemists, data analysts, and software developers to quantify individual biomedical variance and translate it into personalized diagnostics and therapy recommendations, particularly in oncology, pharmacogenetics, infectious disease, and consumer wellness. Its product portfolio spans core software platforms (OncoVariant for genetic variant interpretation and automated drug search for oncologists, TubeLab for laboratory workflow management, BioCore Studio for biomedical data processing from NGS and HPLC/UPLC-MS), laboratory diagnostic services (an Express-PCR lab with capacity for up to 1,000 samples per day and sub-3-hour turnaround), an LC-MS/MS-based biomarker quantification service (initial vitamin panel application), and a direct-to-consumer telomere length self-test (QualityAge) for biological age assessment. The technology stack relies on proprietary AI and machine learning models developed in-house and through EU-funded research consortia (REVERT for metastatic colorectal cancer treatment prediction under HORIZON 2020; BEATsep for sepsis long-term complication prediction under HORIZON EUROPE).
Revenue is generated across five streams: professional services from PCR diagnostics and biomarker quantification, software licensing and subscriptions for OncoVariant and TubeLab, one-time consumer self-test sales through its Shopify storefront and distribution partner QualityLab24, professional services revenue from EU-funded research collaborations, and subscription-based pharmaceutical partnerships for personalized medicine development. The go-to-market is hybrid: direct enterprise sales to healthcare providers, oncologists, and pharmaceutical companies, combined with a DTC e-commerce channel for consumer self-tests. The company took a minority seed investment from FlemingEnterprise Holding GmbH and Blaugold Investment GmbH in January 2019 (mid-seven-figure EUR), and has since grown to approximately 30 employees, opened a new headquarters in 2023, and achieved recognition including the TOP 100 innovation award (2021) with an A+ innovation management rating. Customer concentration leans toward European clinical research institutions and unnamed pharmaceutical partners, with a geographic footprint spanning Germany and the Czech Republic and consortium visibility across six EU countries.
BioVariance firmographics
Firmographics- Name
- BioVariance
- Legal name
- BioVariance GmbH
- Website
- https://biovariance.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioVariance GmbH is a Bavarian precision medicine company that uses proprietary AI and bioinformatics platforms (OncoVariant, TubeLab, BioCore Studio) to deliver personalized diagnostics, genetic variant interpretation for oncologists, PCR and LC-MS/MS laboratory services, and a direct-to-consumer telomere self-test, serving healthcare providers, pharmaceutical partners, and clinical research consortia.
- Ownership category
- akta.pro rank
BioVariance industry classification
Industry- Product category
- Precision Medicine Software & Analytics
- NAICS
- Medical Laboratories (621511), Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where BioVariance is headquartered
LocationHeadquarters
- HQ city
- Tirschenreuth
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
BioVariance business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Services: qPCR-based diagnostic testing services including SARS-CoV-2 testing and variant analysis, with fast turnaround times (under 3 hours)
- Software Products: Sale and licensing of software platforms including OncoVariant and TubeLab for healthcare and laboratory use
- Consumer Self-Tests: Direct-to-consumer telomere length self-tests sold through own Shopify store and partner QualityLab24
- Research Collaborations: EU-funded research projects (REVERT, BEATsep) providing project funding for development of AI/ML solutions in precision medicine
- Pharmaceutical Partnerships: Collaborations with pharmaceutical companies for advancing personalized medicine research and therapy optimization
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
BioVariance product offering
Product offeringCore offering
BioVariance develops and sells AI-powered precision medicine software platforms (OncoVariant for genetic variant interpretation in cancer, TubeLab for laboratory workflow management, BioCore Studio for biomedical data processing) and provides related diagnostic laboratory services. The company offers qPCR-based diagnostic testing (e.g., SARS-CoV-2 with under-3-hour turnaround) and consumer-facing telomere length self-tests, all built on proprietary machine learning and bioinformatics algorithms developed through its interdisciplinary team of biologists, chemists, software developers, and data analysts.
Product overview
BioVariance is a data-driven diagnostics company offering a portfolio of precision medicine products and services. Their core product suite includes OncoVariant (genetic variant interpretation platform for oncologists), TubeLab (laboratory process management software), and BioCore Studio (biomedical data processing platform). They offer consumer-facing genetic tests such as the Telomere Length Self-Test for biological age assessment, and provide laboratory diagnostic services including PCR testing. The products integrate machine learning algorithms for personalized treatment prediction, particularly in oncology and pharmacogenetics. All offerings center on quantifying biomedical variance to improve patient health outcomes through data analysis and interpretation.
Differentiator
Problem solved
Functional benefit
Products and services
- OncoVariant Platform for interpretation of genetic variants in cancer patients that automates drug search for oncologists, simplifying and significantly accelerating the search for suitable medications based on individual patient genetic profiles.
- TubeLab Software for organization and digital monitoring of multi-level laboratory processes, facilitating efficient performance of workflow including sample tracking, processing, and documentation.
- BioCore Studio
Quantifiable outcome
- PCR results delivered in under 3 hours vs 24-48 hours industry standard
- +4 more outcomes
Companies that use BioVariance
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles5 records
BioVariance technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability11 records
Feature6 records
BioVariance partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- BEATsep Research ConsortiumcoreEU HORIZON EUROPE funded project (6.9 million EUR grant) focused on combating long-term effects of sepsis. BioVariance develops AI algorithms to link collected patient data and predict high-risk complications. Consortium includes 9 partners from 6 EU countries including ICRC-FNUSA, CIML, University of Bonn, Comenius University, and others.
- REVERT Project ConsortiumcoreEU HORIZON 2020 funded project for targeted therapy in metastatic colorectal cancer patients. BioVariance contributes machine learning algorithms and AI expertise. Consortium includes specialists from Italy, Spain, Sweden, Luxembourg, Romania, and Germany including physicians, pathologists, biologists, and AI specialists.
- Oberender AGcoreManagement consulting partnership for Internationalization, product development, and sales professionalization. Oberender AG provides operational support for regulatory framework conditions and negotiations with German cost carriers.
- QualityLab24minorDistribution partner for telomere self-test product. Test available for purchase through QualityLab24 online store.
- Bavarian Red Cross (BRK)minorCollaboration for PCR testing operations and establishment of test stations during SARS-CoV-2 pandemic.
- Administrative District Office TirschenreuthminorLocal government partnership for pandemic response and establishment of diagnostic lab in former hospital building.
Scale indicators10 records
Recent moves8 records
Expansion highlights5 records
BioVariance competitors and assessment
Company assessmentDirect peers
- BC Platforms: Genomic and clinical data management platform for precision medicine and pharma R&D — comparable data-infrastructure orientation in the precision-medicine software category.
- Tempus Labs: AI-powered precision medicine company combining molecular data, clinical records, and ML to support oncology and other therapeutic decisions — comparable in combining lab, software, and AI/ML for therapy selection.
- Owkin: AI-for-medical-research company partnering with hospitals and pharma on federated learning models, including oncology and other complex disease areas — directly comparable AI/ML precision-medicine orientation.
- Genedata: Enterprise bioinformatics software platform for processing high-throughput biomedical data (NGS, MS) — directly comparable to BioCore Studio for biomedical data processing pipelines.
- SOPHiA Genetics: AI-driven genomics and clinical decision support platform used by hospitals for variant interpretation and therapy recommendation — directly comparable to BioVariance's OncoVariant and broader precision-medicine positioning.
- Molecular Health: Heidelberg-based software company offering AI-supported molecular diagnostic and therapy decision tools for clinicians — directly comparable German peer in precision-medicine informatics.
Broad incumbents
- Qiagen: Global leader in molecular diagnostics and sample-preparation technologies, including PCR/qPCR assays and bioinformatics — broad incumbent competing across BioVariance's PCR services and bioinformatics portfolio.
- Foundation Medicine: Roche-owned molecular diagnostics and genomic profiling company for oncology therapy selection — broad incumbent and primary reference competitor for OncoVariant.
- NanoString Technologies: Genomics tools and diagnostics provider offering instruments, consumables, and software for spatial biology and molecular profiling — adjacent competitor in molecular biology instrumentation and analysis.
Regional players
- Charité spin-outs / molecular Dx startups (e.g., Targos, Amedes): German/European molecular diagnostics laboratories and reference service providers operating PCR, biomarker quantification, and clinical trial sample handling — comparable as regional precision-medicine lab service peers.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
BioVariance social profiles
Digital presenceBioVariance compliance and trust
Trust signalCompliance3 records
BioVariance financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioVariance leadership team
Management profileNumber of profiles
Profiles3 records
BioVariance funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioVariance M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioVariance
What does BioVariance do?
BioVariance develops and sells AI-powered precision medicine software platforms (OncoVariant for genetic variant interpretation in cancer, TubeLab for laboratory workflow management, BioCore Studio for biomedical data processing) and provides related diagnostic laboratory services. The company offers qPCR-based diagnostic testing (e.g., SARS-CoV-2 with under-3-hour turnaround) and consumer-facing telomere length self-tests, all built on proprietary machine learning and bioinformatics algorithms developed through its interdisciplinary team of biologists, chemists, software developers, and data analysts.
Is BioVariance a public or private company?
BioVariance is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioVariance founded?
BioVariance was founded in 2013. It employs 11 to 50 people.
Where is BioVariance based?
BioVariance is headquartered in Tirschenreuth, Germany, in the Europe region.
How does BioVariance make money?
Five revenue lines are on record. Diagnostic Services are the primary driver. The others are software Products, consumer Self-Tests, research Collaborations and pharmaceutical Partnerships.
Who are BioVariance's main competitors?
Direct peers on record are BC Platforms, Tempus Labs, Owkin, Genedata, SOPHiA Genetics and Molecular Health. Broad incumbents are Qiagen, Foundation Medicine and NanoString Technologies. Charité spin-outs / molecular Dx startups (e.g., Targos, Amedes) is listed as a regional player.
Does BioVariance have an API?
No public API is recorded for BioVariance.
What industry is BioVariance in?
BioVariance's product category is Precision Medicine Software & Analytics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 621511 and its SIC code is 8071.